Literature DB >> 2335452

Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis.

R E Grossman1, D F Chu, D A Lee.   

Abstract

Transcorneal and transscleral iontophoresis were compared to subconjunctival injection (control) in the delivery of gentamicin into rabbit eyes. Gentamicin levels in the corena, aqueous, and vitreous were measured by a fluorescence polarization assay at various time intervals after treatment. A mean peak corneal concentration of 376.1 micrograms/ml was achieved 2 hr after transcorneal iontophoresis. This was significantly higher than the level obtained in control eyes (P = 0.016). A mean peak aqueous humor concentration of 54.8 micrograms/ml occurred 2 hr after transcorneal iontophoresis. This was significantly higher than the peak level of 14.2 micrograms/ml after subconjunctival injection (P = 0.003). Inhibitory levels (approximately 5 micrograms/ml) were maintained in both aqueous and cornea for 8 hr after transcorneal iontophoresis. After transscleral iontophoresis, the mean peak vitreous humor concentration was 53.4 micrograms/ml at 16 hr and remained inhibitory through 24 hr; the peak aqueous level was 23.2 micrograms/ml and remained inhibitory for 24 hr. Peak drug concentrations in the vitreous were significantly higher than control (P = 0.026). Therapeutic vitreous humor levels were not achievable after transcorneal iontophoresis or subconjunctival injection. Potential corneal toxicity of transcorneal iontophoresis was demonstrated by measuring corneal thickness and endothelial cell counts prior to and 3 days after transcorneal iontophoresis of gentamicin and balanced saline solution (BSS) (control). No significant differences existed between eyes treated with gentamicin compared to those treated with BSS or when pre- versus postiontophoresis of gentamicin in the same eyes were compared. Transcorneal and transscleral iontophoresis may be an effective noninvasive method of delivering inhibitory levels of gentamicin to the cornea, aqueous humor, and vitreous for the treatment of intraocular infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335452

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Iodide iontophoresis as a treatment for dry eye syndrome.

Authors:  J Horwath-Winter; O Schmut; E-M Haller-Schober; A Gruber; G Rieger
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

Review 2.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

3.  Efficacy of iontophoresis in the rat cornea.

Authors:  J Frucht-Pery; A Solomon; R Doron; P Ever-Hadani; O Manor; M Shapiro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-12       Impact factor: 3.117

4.  The effect of iodide iontophoresis on the antioxidative capacity of the tear fluid.

Authors:  Gebhard Rieger; Manfred Klieber; Wolfgang Schimetta; Werner Pölz; Sirid Griebenow; Rudolf Winkler; Jutta Horwath-Winter; Otto Schmut; Birgit Spitzer-Sonnleitner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-23       Impact factor: 3.117

5.  Sodium hyaluronate 0.25% used as a vehicle increases the bioavailability of topically administered gentamicin.

Authors:  S F Bernatchez; C Tabatabay; R Gurny
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-03       Impact factor: 3.117

Review 6.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

Review 7.  Recent perspectives in ocular drug delivery.

Authors:  Ripal Gaudana; J Jwala; Sai H S Boddu; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.